Calcium and magnesium use for oxaliplatin-induced neuropathy: A case study to assess how quickly evidence translates into practice

Deirdre R. Pachman, Kathryn J Ruddy, Lindsey R. Sangaralingham, Axel F Grothey, Nilay D Shah, Andreas S Beutler, Joleen M Hubbard, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Substantial research efforts have focused on methods of treating and preventing oxaliplatin-associated neuropathy, the doselimiting toxicity associated with this drug. Administration of intravenous calcium and magnesium (CaMg) before and after oxaliplatin has been the most studied approach to preventing oxaliplatininduced neuropathy. Although early reports demonstrated potential benefit, subsequent larger trials failed to confirm the efficacy of CaMg in preventing this adverse effect. This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice.

Original languageEnglish (US)
Pages (from-to)1097-1101
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number9
StatePublished - Sep 1 2015

Fingerprint

oxaliplatin
Magnesium
Calcium
Intravenous Administration
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

@article{8c1fd8b4d76c4d95bef10b1c530f8c79,
title = "Calcium and magnesium use for oxaliplatin-induced neuropathy: A case study to assess how quickly evidence translates into practice",
abstract = "Substantial research efforts have focused on methods of treating and preventing oxaliplatin-associated neuropathy, the doselimiting toxicity associated with this drug. Administration of intravenous calcium and magnesium (CaMg) before and after oxaliplatin has been the most studied approach to preventing oxaliplatininduced neuropathy. Although early reports demonstrated potential benefit, subsequent larger trials failed to confirm the efficacy of CaMg in preventing this adverse effect. This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice.",
author = "Pachman, {Deirdre R.} and Ruddy, {Kathryn J} and Sangaralingham, {Lindsey R.} and Grothey, {Axel F} and Shah, {Nilay D} and Beutler, {Andreas S} and Hubbard, {Joleen M} and Loprinzi, {Charles Lawrence}",
year = "2015",
month = "9",
day = "1",
language = "English (US)",
volume = "13",
pages = "1097--1101",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Calcium and magnesium use for oxaliplatin-induced neuropathy

T2 - A case study to assess how quickly evidence translates into practice

AU - Pachman, Deirdre R.

AU - Ruddy, Kathryn J

AU - Sangaralingham, Lindsey R.

AU - Grothey, Axel F

AU - Shah, Nilay D

AU - Beutler, Andreas S

AU - Hubbard, Joleen M

AU - Loprinzi, Charles Lawrence

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Substantial research efforts have focused on methods of treating and preventing oxaliplatin-associated neuropathy, the doselimiting toxicity associated with this drug. Administration of intravenous calcium and magnesium (CaMg) before and after oxaliplatin has been the most studied approach to preventing oxaliplatininduced neuropathy. Although early reports demonstrated potential benefit, subsequent larger trials failed to confirm the efficacy of CaMg in preventing this adverse effect. This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice.

AB - Substantial research efforts have focused on methods of treating and preventing oxaliplatin-associated neuropathy, the doselimiting toxicity associated with this drug. Administration of intravenous calcium and magnesium (CaMg) before and after oxaliplatin has been the most studied approach to preventing oxaliplatininduced neuropathy. Although early reports demonstrated potential benefit, subsequent larger trials failed to confirm the efficacy of CaMg in preventing this adverse effect. This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84941752797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941752797&partnerID=8YFLogxK

M3 - Article

C2 - 26358793

AN - SCOPUS:84941752797

VL - 13

SP - 1097

EP - 1101

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 9

ER -